MRI Goes Beyond Brain Atrophy: New Model Maps Cellular-Level Changes in Huntington’s Disease

Conventional magnetic resonance imaging can measure shrinkage in brain regions, but it is difficult for it to explain why tissue disappears. A study published in eLife attempted to bring the lens one level closer: using a diffusion MRI model called Soma and Neurite Density Imaging (SANDI) to estimate changes in cell bodies, neurites, and extracellular space from in vivo images, in hopes of revealing the microscopic structures underlying brain atrophy in Huntington’s disease.

The research team compared 56 patients with Huntington’s disease with 57 age- and sex-matched controls. Multi-shell diffusion images were acquired using a 3-tesla Siemens Connectom scanner, followed by analyses of the caudate nucleus, putamen, globus pallidus, and thalamus. The results showed that patients had lower “apparent soma density” in the basal ganglia, along with higher apparent soma size and extracellular signal fraction; the thalamus did not show the same pattern.

These signals align with known pathology. Huntington’s disease causes progressive loss of medium spiny neurons in the striatum, so lower apparent soma density may reflect neuronal loss, while a higher extracellular signal fraction may indicate reduced tissue density. The study also found that SANDI measures were associated with performance on quantitative motor tests; when included in an analysis together with age, they could explain up to 63% of the variation in striatal atrophy.

However, SANDI provides model parameters inferred from MRI signals, not histological measurements that directly count neurons. Another unresolved finding was that although patients showed lower apparent soma density, there was no significant between-group difference in apparent neurite density. This may involve disease biology, or it may be influenced by the model and sampling methods; the available cross-sectional data are insufficient to draw a conclusion.

### Background

Huntington’s disease is an inherited neurodegenerative disorder caused by a specific genetic mutation that progressively impairs motor, cognitive, and behavioral functions. As gene therapies, cell therapies, and other disease-modifying strategies enter development, trials need more than a record that the brain has already shrunk; they need a way to determine earlier, and more closely in line with the pathological process, whether treatment changes neurodegeneration. If SANDI can reliably track cellular-level changes, it may address the limitation of conventional volumetric imaging, which can show only accumulated damage.

This study has not yet shown that SANDI can predict the course of disease in individual patients, nor has it demonstrated that SANDI is more sensitive than existing imaging measures. The Connectom system used in the study has high-performance gradients and is not commonly available in general hospitals; the data also came from multiple cohorts, and clinical phenotype measurements were not entirely consistent. Bringing this method into multicenter clinical trials will still require larger samples, longitudinal follow-up, validation of its biological meaning against pathological data, and confirmation that the findings can be reproduced on commonly used MRI equipment.